Beximco Pharma plans subsidiary to diversify products

Resumen detallado
Beximco Pharmaceuticals PLC plans to set up a wholly owned subsidiary to manufacture and market herbal medicinal products, as the drug maker seeks to diversify its product…
Beximco Pharmaceuticals PLC plans to set up a wholly owned subsidiary to manufacture and market herbal medicinal products, as the drug maker seeks to diversify its product portfolio and expand its presence in the healthcare market.
The board of Beximco Pharma decided to incorporate the new entity, Beximco Pharma Nutraceuticals Ltd, at a meeting held on 12 November 2026, the company said in a disclosure to the Dhaka Stock Exchange (DSE) yesterday.
At the same meeting, the board appointed SM Rabbur Reza, the company’s chief operating officer, as managing director and a director for five years with immediate effect.
As per the DSE disclosure, the pharmaceutical giant’s proposed subsidiary will have an authorised share capital of Tk 100 crore, divided into 10 crore ordinary shares of Tk 10 each, and an initial paid-up capital of Tk 10 crore, Beximco Pharma said.
The incorporation of the subsidiary and commencement of its operations will be subject to obtaining the necessary statutory and regulatory approvals. The company does not anticipate any material impact on its financial performance in the immediate or medium term from the initiative, it said.
Shares of the drug maker rose 3.97 percent to Tk 149 at the end of yesterday’s trading session.
Beximco Pharma posted an 8 percent year-on-year increase in earnings per share (EPS) to Tk 5.72 in the July-September quarter of 2026, from Tk 5.30 in the same period a year earlier.
Its net operating cash flow per share (NOCFPS), which measures cash generated from core business operations relative to each share, grew 31 percent to Tk 8.06 during the quarter, from Tk 6.14 a year earlier.
Inicio del artículo, extracto de The Daily Star. Para leer el resto, abra el artículo en el sitio del medio.
MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.thedailystar.net)


